TY - JOUR
T1 - The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer
AU - Landt, Solveig
AU - Heidecke, Harald
AU - Reuter, Cora
AU - Korlach, Susanne
AU - Blohmer, Jens Uwe
AU - Lichtenegger, Werner
AU - Heusner, Till
AU - Stoblen, Frank
AU - Thill, Marc
AU - Barinoff, Jana
AU - Sehouli, Jalid
AU - Kümmel, Sherko
PY - 2011/8/1
Y1 - 2011/8/1
N2 - Background/Aim: Angiogenesis plays a key role in tumour growth and metastasis. Expression of angiogenic factors has been suggested as a marker for tumour malignity, and may help to assess a patient's individual prognosis. The present study examines the relationship between angiogenic factor expression, an angiogenesis-based histoscore and clinical tumour criteria. Patients and Methods: A total of 81 patients with cervical cancer who underwent follow-up examinations between October 2002, and June 2005, were enrolled, and serum samples were examined for vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), endostatin and VEGF-Receptor1 by means of an ELISA. Based on an endothelial-cell proliferation assay, an angiogenesis score was calculated. Results: Higher endostatin and VEGF expressions indicated advanced disease, and VEGF allowed for a reliable distinction between patients with non-invasive and these with recurrent disease. There were some plausible correlations between the angiogenesis score and clinical criteria and individual angiogenic factors, but the score's discriminating power appears to be limited. Conclusion: The utility of angiogenesis factor testing notwithstanding, the value of an angiogenesis score for the identification of patients with a worse prognosis, and thus a resulting benefit from more aggressive treatment, is arguable.
AB - Background/Aim: Angiogenesis plays a key role in tumour growth and metastasis. Expression of angiogenic factors has been suggested as a marker for tumour malignity, and may help to assess a patient's individual prognosis. The present study examines the relationship between angiogenic factor expression, an angiogenesis-based histoscore and clinical tumour criteria. Patients and Methods: A total of 81 patients with cervical cancer who underwent follow-up examinations between October 2002, and June 2005, were enrolled, and serum samples were examined for vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), endostatin and VEGF-Receptor1 by means of an ELISA. Based on an endothelial-cell proliferation assay, an angiogenesis score was calculated. Results: Higher endostatin and VEGF expressions indicated advanced disease, and VEGF allowed for a reliable distinction between patients with non-invasive and these with recurrent disease. There were some plausible correlations between the angiogenesis score and clinical criteria and individual angiogenic factors, but the score's discriminating power appears to be limited. Conclusion: The utility of angiogenesis factor testing notwithstanding, the value of an angiogenesis score for the identification of patients with a worse prognosis, and thus a resulting benefit from more aggressive treatment, is arguable.
UR - http://www.scopus.com/inward/record.url?scp=79961178174&partnerID=8YFLogxK
M3 - Journal articles
C2 - 21778317
AN - SCOPUS:79961178174
SN - 0250-7005
VL - 31
SP - 2645
EP - 2649
JO - Anticancer Research
JF - Anticancer Research
IS - 8
ER -
